Clin Pharmacol Ther. 2010 Nov;88(5):634-42. Epub 2010 Sep 22.

A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs.

Merlo-Pich E, Alexander RC, Fava M, Gomeni R.

Source

Neurosciences Center of Excellence for Drug Discovery, GlaxoSmithKline R&D, Verona, Italy. emilio.v.merlo-pich@gsk.com

Abstract

The rate-limiting factor in the discovery of novel antidepressants is the inefficient methodology of traditional multicenter randomized clinical trials (RCTs). We applied a model-based approach to a large clinical database (five RCTs in major depressive disorder (MDD), involving 1,837 patients from 124 recruitment centers) with two objectives: (i) to learn about the role of center-specific placebo response in RCT failure and (ii) to apply what is learned to improve the efficiency of RCTs by enhancing the detection of treatment effect (TE). Sensitivity analysis indicated that center-specific placebo response was the most relevant predictor of RCT failure. To reduce the statistical "noise" generated by centers with nonplausible, excessively high/low placebo responses, we developed an enrichment-window strategy. Clinical trial simulation was used to assess the enrichment strategy applied before the standard statistical analysis, resulting in an overall reduction in failure of RCTs from ~50 to ~10%.

Comment in

PMID:: 20861834; [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

MeSH Terms

Substances

Antidepressive Agents

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials. [Clin Pharmacol Ther. 2010]
The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials.
Mallinckrodt CH, Prucka WR. Clin Pharmacol Ther. 2010 Nov; 88(5):592-4.
Review Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. [Eur Neuropsychopharmacol. 2009]
Review Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
Papakostas GI, Fava M. Eur Neuropsychopharmacol. 2009 Jan; 19(1):34-40. Epub 2008 Sep 26.
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. [J Clin Psychopharmacol. 2006]
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.
Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. J Clin Psychopharmacol. 2006 Feb; 26(1):56-60.
Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment? [Crit Care Med. 2009]
Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment?
Roozenbeek B, Maas AI, Lingsma HF, Butcher I, Lu J, Marmarou A, McHugh GS, Weir J, Murray GD, Steyerberg EW, et al. Crit Care Med. 2009 Oct; 37(10):2683-90.
Review Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. [J Clin Psychiatry. 2011]
Review Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
Tedeschini E, Fava M, Papakostas GI. J Clin Psychiatry. 2011 Jan; 72(1):98-118. Epub 2010 Nov 2.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

A new population-enrichment strategy to improve efficiency of placebo-controlled...
A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs.
Clin Pharmacol Ther. 2010 Nov ;88(5):634-42. Epub 2010 Sep 22 .

PubMed
Anticancer properties of artemisinin derivatives and their targeted delivery by ...
Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation.
Int J Pharm. 2008 Apr 16 ;354(1-2):28-33. Epub 2007 Sep 6 .

PubMed
Clostridium difficile: new therapeutic options.
Clostridium difficile: new therapeutic options.
Curr Opin Pharmacol. 2007 Oct ;7(5):455-8. Epub 2007 Jul 23 .

PubMed
Treatment of Clostridium difficile infection.
Treatment of Clostridium difficile infection.
Clin Infect Dis. 2008 Jan 15 ;46 Suppl 1:S32-42.

PubMed
Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.
Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.
Expert Rev Anti Infect Ther. 2006 Dec ;4(6):939-45.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs.

Source

Abstract

Comment in

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Education

Medical

Supplemental Content

Related citations

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information